{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:19:10Z","timestamp":1793949550432,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/J00460X\/1"],"award-info":[{"award-number":["MR\/J00460X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00213-017-4771-x","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T02:46:56Z","timestamp":1510109216000},"page":"399-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":855,"title":["Psilocybin with psychological support for treatment-resistant depression: six-month follow-up"],"prefix":"10.1007","volume":"235","author":[{"given":"R. L.","family":"Carhart-Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bolstridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M. J.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. E.","family":"Erritzoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kaelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Giribaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bloomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Rickard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Feilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. V.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"key":"4771_CR1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1177\/0269881115581980","volume":"29","author":"J Amsterdam van","year":"2015","unstructured":"van Amsterdam J, Nutt D, Phillips L et al (2015) European rating of drug harms. J Psychopharmacol 29:655\u2013660","journal-title":"J Psychopharmacol"},{"key":"4771_CR2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA et al (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29:289\u2013299","journal-title":"J Psychopharmacol"},{"key":"4771_CR3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","volume":"14","author":"KR Bonson","year":"1996","unstructured":"Bonson KR, Buckholtz JW, Murphy DL (1996) Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14:425\u2013436","journal-title":"Neuropsychopharmacology"},{"key":"4771_CR4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042421","volume":"7","author":"JC Bouso","year":"2012","unstructured":"Bouso JC, Gonzalez D, Fondevila S et al (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study. PLoS One 7:e42421","journal-title":"PLoS One"},{"key":"4771_CR5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.psyneuen.2010.08.011","volume":"36","author":"I Branchi","year":"2011","unstructured":"Branchi I (2011) The double edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. Psychoneuroendocrinology 36:339\u2013351","journal-title":"Psychoneuroendocrinology"},{"key":"4771_CR6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/0269881114531666","volume":"28","author":"T Buchborn","year":"2014","unstructured":"Buchborn T, Schroder H, Hollt V et al (2014) Repeated lysergic acid diethylamide in an animal model of depression: normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling. J Psychopharmacol 28:545\u2013552","journal-title":"J Psychopharmacol"},{"key":"4771_CR7","doi-asserted-by":"crossref","unstructured":"Carhart-Harris RL and Goodwin GM. (2017) The therapeutic potential of psychedelic drugs: past, present and future. Neuropsychopharmacology","DOI":"10.1038\/npp.2017.84"},{"key":"4771_CR8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/02791072.2013.825034","volume":"45","author":"RL Carhart-Harris","year":"2013","unstructured":"Carhart-Harris RL, Nutt DJ (2013) Experienced drug users assess the relative harms and benefits of drugs: a web-based survey. J Psychoactive Drugs 45:322\u2013328","journal-title":"J Psychoactive Drugs"},{"key":"4771_CR9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S2215-0366(16)30217-6","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Nutt DJ (2016) Question-based drug development for psilocybin - authors\u2019 reply. Lancet Psychiatry 3:807","journal-title":"Lancet Psychiatry"},{"key":"4771_CR10","doi-asserted-by":"crossref","unstructured":"Carhart-Harris RL, Nutt DJ (2017) Serotonin and brain function: a tale of two receptors. J Psychopharmacol 269881117725915","DOI":"10.1177\/0269881117725915"},{"key":"4771_CR11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3:619\u2013627","journal-title":"Lancet Psychiatry"},{"key":"4771_CR12","doi-asserted-by":"crossref","unstructured":"Carhart-Harris RL et al (2017) Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Nat Sci Rep 7(1):13187","DOI":"10.1038\/s41598-017-13282-7"},{"key":"4771_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4088\/JCP.v60n0110","volume":"60","author":"LL Carpenter","year":"1999","unstructured":"Carpenter LL, Jocic Z, Hall JM et al (1999) Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 60:45\u201349","journal-title":"J Clin Psychiatry"},{"key":"4771_CR14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y et al (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513\u2013520","journal-title":"J Nerv Ment Dis"},{"key":"4771_CR15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"R Griffiths","year":"2008","unstructured":"Griffiths R, Richards W, Johnson M et al (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22:621\u2013632","journal-title":"J Psychopharmacol"},{"key":"4771_CR16","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA et al (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30:1181\u20131197","journal-title":"J Psychopharmacol"},{"key":"4771_CR17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS et al (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71\u201378","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"4771_CR18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S2215-0366(17)30038-X","volume":"4","author":"R Gueorguieva","year":"2017","unstructured":"Gueorguieva R, Chekroud AM, Krystal JH (2017) Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. Lancet Psychiatry 4(3):230\u2013237","journal-title":"Lancet Psychiatry"},{"key":"4771_CR19","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I (2016) Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol 30:1259\u20131267","journal-title":"J Psychopharmacol"},{"key":"4771_CR20","doi-asserted-by":"crossref","unstructured":"Hendricks PS, Thorne CB, Clark CB, et al (2015) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol 29(3):280\u20138","DOI":"10.1177\/0269881114565653"},{"key":"4771_CR21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603\u2013620","journal-title":"J Psychopharmacol"},{"key":"4771_CR22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP et al (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28:983\u2013992","journal-title":"J Psychopharmacol"},{"key":"4771_CR23","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s00213-015-4014-y","volume":"232","author":"M Kaelen","year":"2015","unstructured":"Kaelen M, Barrett FS, Roseman L et al (2015) LSD enhances the emotional response to music. Psychopharmacology 232:3607\u20133614","journal-title":"Psychopharmacology"},{"key":"4771_CR24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs TS, Johansen PO (2012) Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 26:994\u20131002","journal-title":"J Psychopharmacol"},{"issue":"10","key":"4771_CR25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076882","volume":"8","author":"N Kubitz","year":"2013","unstructured":"Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N (2013) Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One 8(10):e76882","journal-title":"PLoS One"},{"key":"4771_CR26","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK et al (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67:1735\u20131740","journal-title":"J Clin Psychiatry"},{"key":"4771_CR27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00213-004-2044-y","volume":"179","author":"BA Nic Dhonnchadha","year":"2005","unstructured":"Nic Dhonnchadha BA, Ripoll N, Clenet F et al (2005) Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test. Psychopharmacology 179:418\u2013429","journal-title":"Psychopharmacology"},{"key":"4771_CR28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","volume":"37","author":"L Osorio Fde","year":"2015","unstructured":"Osorio Fde L, Sanches RF, Macedo LR et al (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr 37:13\u201320","journal-title":"Rev Bras Psiquiatr"},{"key":"4771_CR29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4088\/JCP.v60n0410","volume":"60","author":"RB Ostroff","year":"1999","unstructured":"Ostroff RB, Nelson JC (1999) Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 60:256\u2013259","journal-title":"J Clin Psychiatry"},{"key":"4771_CR30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pnpbp.2014.04.013","volume":"54","author":"AC Petit","year":"2014","unstructured":"Petit AC, Quesseveur G, Gressier F et al (2014) Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 54:76\u201382","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"4771_CR31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2015.12.022","volume":"105","author":"G Qesseveur","year":"2016","unstructured":"Qesseveur G, Petit AC, Nguyen HT et al (2016) Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: a translational approach. Neuropharmacology 105:142\u2013153","journal-title":"Neuropharmacology"},{"key":"4771_CR32","doi-asserted-by":"crossref","DOI":"10.7312\/columbia\/9780231174060.001.0001","volume-title":"Sacred knowledge: psychedelics and religious experiences","author":"WA Richards","year":"2015","unstructured":"Richards WA (2015) Sacred knowledge: psychedelics and religious experiences. Columbia University Press, New York"},{"key":"4771_CR33","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30:1165\u20131180","journal-title":"J Psychopharmacol"},{"key":"4771_CR34","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/0269881116679368","volume":"30","author":"JJ Rucker","year":"2016","unstructured":"Rucker JJ, Jelen LA, Flynn S et al (2016) Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol 30:1220\u20131229","journal-title":"J Psychopharmacol"},{"key":"4771_CR35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF, de Lima Osorio F, Dos Santos RG et al (2016) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol 36:77\u201381","journal-title":"J Clin Psychopharmacol"},{"key":"4771_CR36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 5:e12412","journal-title":"PLoS One"},{"key":"4771_CR37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/15733998113099990003","volume":"6","author":"G Thomas","year":"2013","unstructured":"Thomas G, Lucas P, Capler NR et al (2013) Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev 6:30\u201342","journal-title":"Curr Drug Abuse Rev"},{"key":"4771_CR38","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A et al (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897\u20133902","journal-title":"Neuroreport"},{"key":"4771_CR39","doi-asserted-by":"crossref","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R (2017) Patients\u2019 accounts of increased \u2018connection\u2019 and \u2018acceptance\u2019 after psilocybin for treatment-resistant depression. J Humanist Psychol 57(5):520\u2013564","DOI":"10.1177\/0022167817709585"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-017-4771-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4771-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4771-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T06:33:06Z","timestamp":1523601186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-017-4771-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["4771"],"URL":"https:\/\/doi.org\/10.1007\/s00213-017-4771-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,8]]}}}